5608 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Solit
    Solit
  4. Morris
    Morris
  5. Bajorin
    Bajorin
  6. Rosenberg
    Rosenberg
  7. Berger
    Berger
  8. Iyer
    Iyer
  9. Reuter
    Reuter
  10. Feldman
    Feldman

Groups

  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)
  7. Surgery (1000)
  8. Epidemiology and Biostatistics (864)
  9. Survivorship Research (773)
  10. Urology (769)
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Healthcare resource utilization (HCRU) and costs for patients (pts) with metastatic renal cell carcinoma (mRCC) receiving first-line (LOT1) pembrolizumab plus axitinib (P+A) or ipilimumab plus nivolumab (I+N)
    Meeting Abstract

    Shah, N. J.; Shinde, R.; Moore, K.; Sainski-Nguyen, A.; Le, L.; Cao, F.; Song, R.; Singhal, P.; Motzer, R. J.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib in patients with advanced or metastatic clear cell renal cell (ccRCC) carcinoma who have received front-line treatment (NCT04300140)
    Meeting Abstract

    Shah, N. J.; Beckermann, K.; Vogelzang, N. J.; Mao, S. S.; Ornstein, M. C.; Hammers, H. J.; Gao, X.; McDermott, D. F.; Haas, N. B.; Yan, H.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Cross-trial validation of molecular subtypes in patients with metastatic clear cell renal cell carcinoma (RCC): The JAVELIN Renal 101 experience
    Meeting Abstract

    Saliby, R. M.; Jammihal, T.; Labaki, C.; Xie, W.; Motzer, R. J.; Powles, T.; Rini, B. I.; Albiges, L.; Pal, S. K.; McKay, R. R.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Gene-by-gene analysis in the MAGNITUDE study of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations
    Meeting Abstract

    Sandhu, S.; Attard, G.; Olmos, D.; Efstathiou, E.; Castro, E.; Rathkopf, D. E.; Smith, M. R.; Roubaud, G.; Small, E. J.; Gomes, A. J.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Long-term outcomes in EV-301: 24-month findings from the phase 3 trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma
    Meeting Abstract

    Rosenberg, J. E.; Powles, T.; Sonpavde, G. P.; Loriot, Y.; Duran, I.; Lee, J. L.; Matsubara, N.; Vulsteke, C.; Castellano, D. E.; Mamtani, R.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Allelic dosage of RB1 drives CDK4/6 inhibitor treatment resistance in metastatic breast cancer
    Meeting Abstract

    Safonov, A. M.; Bandlamudi, C.; Selenica, P.; Marra, A.; Ferraro, E.; Mandelker, D.; Solit, D. B.; Berger, M. F.; Norton, L.; Powell, S. N.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Rao, A.; Heller, G.; Ryan, C. J.; VanderWeele, D. J.; Lewis, L. D.; Tan, A.; Watt, C.; Chen, R. C.; Kohli, M.; Barata, P. C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Incorporation of intrapatient response heterogeneity using (18)F-NaF PET/CT imaging improves outcome prediction models for metastatic prostate cancer patients
    Meeting Abstract

    Perk, T. G.; Yip, S. S. F.; Weisman, A. J.; Houshmandi, S. S.; Heath, E. I.; Morris, M. J.; Madan, R. A.; McNeel, D. G.; Apolo, A. B.; Kyriakopoulos, C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Immunogenomic characterization of biliary tract cancers: Biomarker enrichment for benefit to immune checkpoint blockade
    Meeting Abstract

    Park, W.; Keane, F.; Bandlamudi, C.; Donoghue, M.; de Lara, P. T.; Harding, J. J.; Khalil, D.; McKinnell, Z.; Sterpi, M.; Cao, W.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Building a model to predict the risk of multiple severe neurotoxicities in cancer survivors after cisplatin treatment
    Meeting Abstract

    Nakshatri, S.; Shuey, M.; Shahbazi, M.; Trendowski, M.; Dinh, P. C.; Feldman, D. R.; Hamilton, R. J.; Vaughn, D. J.; Fung, C.; Kollmannsberger, C. K.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save